Corbus Pharma (CRBP) Misses Q4 EPS by 4c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Corbus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates
March 12, 2019 7:01 AM EDTÂ Pipeline of rationally-designed synthetic cannabinoids position Corbus to become the leader in treating inflammatory and fibrotic diseases by targeting the endocannabinoid system (ECS) Â Continued progress in four ongoing clinical studies as lenabasum moves towards expected 2020 topline data readouts... More
